Codexis (CDXS) Capital Expenditures (2010 - 2026)
Codexis (CDXS) posted quarterly Capital Expenditures of $604000.0 for Q1 2026, down 51.87% year-over-year from $1.3 million in Q1 2025, and down 85.82% quarter-over-quarter from $4.3 million in Q4 2025.
Codexis (CDXS) Capital Expenditures (2010 - 2026) Analysis & Trends
Codexis' Capital Expenditures history runs 17 years deep, the most recent figure standing at $604000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 51.87% year-over-year to $604000.0; the TTM figure through Mar 2026 stood at $3.8 million (down 13.77% YoY), while the FY2025 annual figure was $4.5 million, up 3.86% from the prior year.
- Capital Expenditures for Q1 2026 stood at $604000.0, down from $4.3 million in the prior quarter.
- The five-year high for Capital Expenditures was $5.1 million in Q1 2022, with the low at -$7.4 million in Q4 2022.
- The 5-year median for Capital Expenditures is $1.3 million (2025), against an average of $864411.8.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures surged 905.39% in 2022, then slumped 405.57% in 2025.
- Codexis' Capital Expenditures stood at -$7.4 million in 2022, then surged by 157.22% to $4.3 million in 2023, then declined by 4.77% to $4.1 million in 2024, then climbed by 5.0% to $4.3 million in 2025, then tumbled by 85.82% to $604000.0 in 2026.
- Business Quant data shows CDXS's Capital Expenditures at $604000.0 in Q1 2026, $4.3 million in Q4 2025, and $164000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Codexis | 152.06 Mn | 97.14 Mn | 11.40 Mn | 470,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 470,000.00 |
| Jun 30, 2026 | 470,000.00 |
| Mar 31, 2026 | 604,000.00 |
| Mar 31, 2026 | 604,000.00 |
| Dec 31, 2025 | 4.26 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Sep 30, 2025 | 164,000.00 |
| Sep 30, 2025 | 164,000.00 |
| Jun 30, 2025 | -1.21 Mn |
| Jun 30, 2025 | -1.21 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 4.06 Mn |
| Dec 31, 2024 | 4.06 Mn |
| Sep 30, 2024 | -1.28 Mn |
| Sep 30, 2024 | -1.28 Mn |
| Jun 30, 2024 | 395,000.00 |
| Jun 30, 2024 | 395,000.00 |
| Mar 31, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.13 Mn |